reviewantagonists of angiotensin II receptors of type Itelmisartanarterial hypertensionONTARGETTRNSCENDONTARGETTRNSCENDобзорантагонисты рецепторов 1-го типа ангиотензина Птелмисартанартериальная гипертония1.Jackson E. R., Garrison J. С. Renin and angiotensin. In: Hardman J. G., Limbird L. E., eds. Goodman and Gilinan's the pharmacological basis of therapeutics. 9"' ed. New York: Mc- Graw-Hill; 1996. 733-758.2.Oliverio M. L., Coffman Т. М. Angiotensin II receptors: new targets for antihypertensive therapy. Clin. Cardiol. 1997; 20: 3-6.3.Neutel J. M., Smith D. H. G. Dose response and antihypertensive efficacy of the ATI receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv. Ther. 1998; 15: 206-217.4.Wienner W., Hauel N. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonists, BIBR277. Br. J. Pharmacol. 1993; 110: 245-255.5.Freytag F., Holwerda N. I., Karlberg В. Е. et al. Long - term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety. Blood Pressure 2002; 11: 173-181.6.Neutel J. M., Klein C., Meinicke T. W. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medication. Ibid. 302-309.7.Asmar R. Effect of telmisartan on arterial distensibility and central blood pressure in parients with mild to moderate hypertension and type 2 diabetes mellitus. JRAAS 2001; 2: S8- SU.8.McClellan K. J., Markham A. Telmisartan. Drugs 1998; 56: 1039-1044.9.LacourciereI., Lenis I., Orchard R. et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Pressure Monitor 1998; 3: 295-302.10.Elliott H. L. The efficacy and safety of telmisartan compared to atenolol and placebo in patients with hypertension. Am. J. Hypertension 1998; II: 124-131.11.Smith D. H. C., Neutel J. M., Morgenstern P. Once - daily telmisartan compared with enalapril in the treatment of hypertension. Adv.Ther. 1998; 15: 229-240.12.Neutel J. M., Frishman W. Е., Pari! S. et al. Comparison of telmisartan with lisinopril in patients with mild - to - moderate hypertension. Am. J. Ther. 1999; 6: 161 - 166.13.Mallion J. M., Siche J. P., Lacourciere I. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild - to - moderate hypertension. J. Hum. Hypertens. 1999; 13: 657-664.14.Sharpe M., Jarvis В., Goa K. L. Telmisartan. A review of its use in hypertension. Drugs 2001; 61: 1501 - 1529.15.Neutel J. M., Smith D. H. G., Reilly F.A. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Int. J. Clin. Pract. 1999; 53 : 1-4.16.Lacourciere I. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Int. J. Clin. Pract. 1999; 53: 99-103.17.World Health Organisation - International Society of Hypertension. Guidelines for the management of hypertension. Guidelines Subcommittee. J. Hypertens. 1999; 17: 151 - 183.18.Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Экспертный совет Всероссийского научного общества кардиологов. Арт. гипертенз. - 2002; (Прил. 1): 1-14.19.Dahlof В., Devereux R. В., Kjeldsen S. E. et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:1004-1010.20.The heart outcomes prevention evaluation study investigators. Effects of an angiotensin - converting - enzyme inhibitor, ramipril on cardiovascular events in high - risk patients. N.Engl. J. Med. 2000; 342: 145-153.